查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1454092

冠狀病毒疫苗至2030年的的市場預測：按疫苗類型、年齡層、給藥途徑、分銷管道、技術和地區的全球分析

Coronavirus Vaccine Market Forecasts to 2030 - Global Analysis By Vaccine Type, Age Group, Route of Administration, Distribution Channel, Technology and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球新冠疫苗市場規模將達到 439 億美元，預計年複合成長率為 9.4%，到2030年達到 823 億美元。

冠狀病毒疫苗是一種醫療物質，目的是提供對 SARS-CoV-2（引起 COVID-19 的新型冠狀病毒）的免疫力。它刺激人體的免疫系統辨識和中和病毒，預防感染或減輕感染症狀的嚴重。大多數疫苗都針對病毒用來進入人類細胞的刺突蛋白。全球已開發並授權緊急使用多種類型的疫苗，包括mRNA疫苗、病毒載體疫苗、蛋白質亞次單位疫苗和去活化病毒疫苗。

據美國國立衛生研究院（NIH）表示，Pfizer-BioNTech COVID-19 疫苗於2021年 8月 23 日獲得 FDA 商業化核准。

世界的迫切需求

COVID-19 大流行造成了前所未有的全球影響，造成廣泛的疾病、死亡、經濟混亂和社會動盪。疫苗被認為是減少病毒傳播、減輕醫療系統負擔並最終拯救生命的重要工具。此外，政府、醫療機構和公眾都敏銳地意識到大規模開發、生產和分發疫苗的迫切需求。新病毒株的出現進一步加劇了這種緊迫性，凸顯了在疫苗開發和加速市場需求方面持續保持警惕和適應的必要性。

製造限制

全球對 COVID-19 疫苗的快速需求導致生產能力緊張，導致供不應求、生產延誤和分銷挑戰。造成這些限制的因素有很多，包括疫苗生產過程的複雜性、疫苗生產的生產設施有限以及缺乏原料和專用設備。此外，mRNA 疫苗配方中使用的脂質奈米顆粒等關鍵成分的短缺可能會擾亂生產計劃並限制生產能力。因此，製造限制是阻礙市場需求的主要因素。

政府支持

由於 COVID-19 大流行為公共衛生帶來了前所未有的挑戰，世界各國政府投入大量資源、資金和監管支持，以加快疫苗的開發、生產和分配工作。此外，各國政府也向製藥公司和研究機構提供財務投資、研究津貼獎勵，以加快疫苗開發進度並擴大生產能力。因此，政府的支持是拉動市場需求的因素。

對疫苗功效和安全性的擔憂

對疫苗功效和安全性的擔憂是冠狀病毒疫苗市場的主要限制。對疫苗功效的擔憂與疫苗預防感染或降低疾病嚴重程度的程度有關。對疫苗安全性的擔憂還包括潛在的副作用和長期健康影響。有關疫苗接種後罕見但嚴重不良事件（例如凝血障礙或心肌炎）的報告引起了人們的擔憂，削弱了公眾對疫苗安全性的信心，並影響了市場成長。

COVID-19 的影響

COVID-19 對冠狀病毒疫苗市場的影響是深遠且多方面的。 COVID-19 促使科學家、研究人員、製藥公司和政府之間進行前所未有的合作，加速了疫苗開發的進程。此外，疫情需要快速部署 mRNA 和病毒載體平台等創新疫苗技術，在創紀錄的時間內開發和核准多種 COVID-19 疫苗。

RNA疫苗產業預計在預測期內規模最大

RNA疫苗領域估計佔據最大佔有率。這些疫苗使用基於傳訊RNA（mRNA）的新技術來指導體內細胞產生病毒蛋白，引發對病毒的免疫反應。開發 RNA 疫苗具有多種優勢，包括快速生產和擴充性。此外，RNA疫苗可以透過更新其mRNA序列來輕鬆修改以針對新的突變病毒，以匹配新的病毒株，使其可用於對抗不斷演變的流行病，具有更大的多功能性和適應性。

重組疫苗產業預計在預測期內年複合成長率最高

預計重組疫苗產業在預測期內將出現良好成長。這些疫苗是利用重組 DNA 技術開發的，該技術將 SARS-CoV-2 病毒的特定基因（例如編碼刺突蛋白的基因）插入宿主細胞（例如酵母或哺乳動物細胞）中，以產生病毒蛋白。重組疫苗不含活病毒顆粒，因此不存在致病風險。這使得它適合免疫系統較弱或有其他健康問題的人。此外，重組疫苗生產具有高度擴充性，可快速擴大規模以滿足全球需求。

佔有率最大的地區

在估計期間，北美佔據了最大的市場佔有率。北美處於疫苗創新的前沿，總部位於該地區的幾家主要製藥公司率先開發了 COVID-19 疫苗。這些公司利用mRNA和重組DNA等最尖端科技快速開發高效、安全的疫苗。此外，北美各國政府提供大量財政投資、監管支持和採購舉措，以加速疫苗開發並確保其人群廣泛獲得疫苗。

年複合成長率最高的地區：

由於亞太地區人口眾多、醫療保健多元化以及新興經濟體的存在，預計亞太地區在預測期內將出現盈利成長。特別是中國和印度已成為疫苗生產的主要參與者，生產大量的 COVID-19 疫苗供國內使用和全球分銷。這些國家利用其生產能力和廣泛的疫苗生產基礎設施向國內和國際市場供應疫苗。此外，亞太地區多個國家積極參與疫苗研發，為全球抗擊疫情做出貢獻。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球冠狀病毒疫苗市場：依疫苗類型

  • 重新利用疫苗
  • 去活化病毒
  • 非複製病毒載體
  • 蛋白質次單元
  • DNA疫苗
  • RNA疫苗

第6章 全球冠狀病毒疫苗市場：依年齡層

  • 12-18歲
  • 18+

第7章 全球冠狀病毒疫苗市場：依給藥途徑分類

  • 合成疫苗
  • 皮內
  • 肌肉注射
  • 鼻內
  • 其他給藥途徑

第8章 全球冠狀病毒疫苗市場：依通路分類

  • 醫院和診所
  • 政府機關
  • 疫苗接種中心
  • 其他分銷管道

第9章 全球冠狀病毒疫苗市場：依技術分類

  • 合成疫苗
  • 重組疫苗
  • 減毒活病毒疫苗
  • 常規疫苗
  • 其他技術

第10章 全球冠狀病毒疫苗市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Moderna
  • AstraZeneca
  • Sinopharm
  • Pfizer-BioNTech
  • Sinovac
  • Johnson & Johnson
  • Serum Institute of India
  • Bharat Biotech
  • Gamaleya Research Institute
  • Novavax
  • CureVac
  • CanSino Biologics
  • Sanofi-GSK
  • GlaxoSmithKline
  • Entos Pharmaceuticals
Product Code: SMRC25644

According to Stratistics MRC, the Global Coronavirus Vaccine Market is accounted for $43.9 billion in 2023 and is expected to reach $82.3 billion by 2030 growing at a CAGR of 9.4% during the forecast period. A Coronavirus Vaccine is a medical substance developed to provide immunity against the novel coronavirus, SARS-CoV-2, which causes COVID-19. It stimulates the body's immune system to recognize and neutralize the virus, preventing infection or reducing the severity of symptoms if exposure occurs. Most vaccines target the virus's spike protein, which it uses to enter human cells. Different types of vaccines, including mRNA, viral vector, protein subunit, and inactivated virus vaccines, have been developed and authorized for emergency use globally.

According to the National Institutes of Health (NIH), the Pfizer-BioNTech COVID-19 vaccine received FDA approval for commercialization on 23 August 2021.

Market Dynamics:

Driver:

Urgent global need

The COVID-19 pandemic had unprecedented global impact, causing widespread illness, death, economic disruption, and social upheaval. Vaccines are recognized as a critical tool in controlling the spread of the virus, reducing the burden on healthcare systems, and ultimately saving lives. Moreover, governments, healthcare organizations, and the public are acutely aware of the urgency to develop, produce, and distribute vaccines on a massive scale. The urgency is further heightened by the emergence of new variants of the virus, emphasizing the need for continued vigilance and adaptation in vaccine development, which has accelerated market demand.

Restraint:

Manufacturing constraints

The rapid global demand for COVID-19 vaccines has strained manufacturing capacities, leading to supply shortages, delays in production, and distribution challenges. Several factors contribute to these constraints, including the complexity of vaccine production processes, limited manufacturing facilities equipped for vaccine production, and shortages of raw materials and specialized equipment. Additionally, shortages of critical components, such as lipid nanoparticles used in mRNA vaccine formulations, can disrupt manufacturing timelines and limit production capacity. As a result, manufacturing constraints are a significant factor hampering market demand.

Opportunity:

Government support

With the COVID-19 pandemic posing unprecedented public health challenges, governments worldwide have mobilized substantial resources, funding, and regulatory support to accelerate vaccine development, production, and distribution efforts. Additionally, governments have provided financial investments, research grants, and incentives to pharmaceutical companies and research institutions to expedite vaccine development timelines and scale up manufacturing capacity. Therefore, government support is a factor propelling market demand.

Threat:

Vaccine efficacy and safety concerns

Vaccine efficacy and safety concerns represent a significant restraint in the coronavirus vaccine market. Concerns regarding vaccine efficacy relate to how well a vaccine prevents infection or reduces the severity of the disease. Additionally, safety concerns regarding vaccines encompass potential adverse reactions, side effects, or long-term health implications. Reports of rare but serious adverse events following vaccination, such as blood clotting disorders or myocarditis, have raised concerns, eroded public confidence in vaccine safety, and impacted market growth.

Covid-19 Impact

The impact of COVID-19 on the coronavirus vaccine market has been profound and multifaceted. COVID-19 spurred unprecedented collaboration among scientists, researchers, pharmaceutical companies, and governments to accelerate vaccine development timelines. Moreover, the pandemic necessitated the rapid deployment of innovative vaccine technologies, such as mRNA and viral vector platforms, leading to the development and approval of multiple COVID-19 vaccines in record time.

The RNA vaccine segment is expected to be the largest during the forecast period

The RNA vaccine segment is estimated to hold the largest share. These vaccines utilize a novel technology based on messenger RNA (mRNA) to instruct cells in the body to produce a viral protein, triggering an immune response against the virus. The development of RNA vaccines offers several advantages, including rapid production and scalability. Additionally, RNA vaccines can be easily modified to target new variants of the virus by updating the mRNA sequence to match emerging strains, enhancing their versatility and adaptability in combating the evolving nature of the pandemic.

The recombinant vaccines segment is expected to have the highest CAGR during the forecast period

The recombinant vaccines segment is anticipated to have lucrative growth during the forecast period. These vaccines are developed using recombinant DNA technology, where specific genes from the SARS-CoV-2 virus, such as those encoding the spike protein, are inserted into host cells, such as yeast or mammalian cells, to produce viral proteins. Recombinant vaccines do not contain live virus particles, eliminating the risk of causing disease. This makes them suitable for individuals with compromised immune systems or other health conditions. Furthermore, recombinant vaccine production is highly scalable and can be rapidly scaled up to meet global demand.

Region with largest share:

North America commanded the largest market share during the extrapolated period. North America has been at the forefront of vaccine innovation, with several leading pharmaceutical companies headquartered in the region spearheading the development of COVID-19 vaccines. These companies have leveraged cutting-edge technologies, such as mRNA and recombinant DNA, to rapidly develop vaccines with high efficacy and safety profiles. Furthermore, governments in North America have provided substantial financial investments, regulatory support, and procurement initiatives to expedite vaccine development and ensure widespread access to vaccines for their populations.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, due to its large population, diverse healthcare landscape, and emerging economies. China and India, in particular, have emerged as key players in vaccine manufacturing, producing large quantities of COVID-19 vaccines for domestic use and global distribution. These countries have leveraged their manufacturing capabilities and extensive vaccine production infrastructure to supply vaccines to both domestic and international markets. Moreover, several countries in the Asia-Pacific region have actively participated in vaccine research and development, contributing to the global effort to combat the pandemic.

Key players in the market

Some of the key players in the Coronavirus Vaccine Market include Moderna, AstraZeneca, Sinopharm, Pfizer-BioNTech, Sinovac, Johnson & Johnson, Serum Institute of India, Bharat Biotech, Gamaleya Research Institute, Novavax, CureVac, CanSino Biologics, Sanofi-GSK, GlaxoSmithKline and Entos Pharmaceuticals.

Key Developments:

In November 2023, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.

In July 2023, AstraZeneca, a global biopharmaceutical company, announced collaboration with Absci Corporation. This collaboration combines Absci's Integrated Drug Creation(TM) platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate.

In January 2022, Pfizer Inc. and BioNTech SE announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.

In April 2020, Johnson & Johnson announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to support the manufacturing of its lead investigational COVID-19 vaccine candidate.

Vaccine Types Covered:

  • Repurposed Vaccines
  • Inactivated Virus
  • Non-replicating Viral Vector
  • Protein Subunit
  • DNA Vaccine
  • RNA Vaccine

Age Groups Covered:

  • 12 to 18
  • Above 18

Route of Administrations Covered:

  • Intradermal
  • Intramuscular
  • Intranasal
  • Other Route of Administrations

Distribution Channels Covered:

  • Hospitals and Clinics
  • Government Entities
  • Vaccination Centers
  • Other Distribution Channels

Technologies Covered:

  • Synthetic Vaccines
  • Recombinant Vaccines
  • Live Attenuated Vaccines
  • Conventional Vaccines
  • Other Technologies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Coronavirus Vaccine Market, By Vaccine Type

  • 5.1 Introduction
  • 5.2 Repurposed Vaccines
  • 5.3 Inactivated Virus
  • 5.4 Non-replicating Viral Vector
  • 5.5 Protein Subunit
  • 5.6 DNA Vaccine
  • 5.7 RNA Vaccine

6 Global Coronavirus Vaccine Market, By Age Group

  • 6.1 Introduction
  • 6.2 12 to 18
  • 6.3 Above 18

7 Global Coronavirus Vaccine Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Synthetic Vaccines
  • 7.3 Intradermal
  • 7.4 Intramuscular
  • 7.5 Intranasal
  • 7.6 Other Route of Administrations

8 Global Coronavirus Vaccine Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospitals and Clinics
  • 8.3 Government Entities
  • 8.4 Vaccination Centers
  • 8.5 Other Distribution Channels

9 Global Coronavirus Vaccine Market, By Technology

  • 9.1 Introduction
  • 9.2 Synthetic Vaccines
  • 9.3 Recombinant Vaccines
  • 9.4 Live Attenuated Vaccines
  • 9.5 Conventional Vaccines
  • 9.6 Other Technologies

10 Global Coronavirus Vaccine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Moderna
  • 12.2 AstraZeneca
  • 12.3 Sinopharm
  • 12.4 Pfizer-BioNTech
  • 12.5 Sinovac
  • 12.6 Johnson & Johnson
  • 12.7 Serum Institute of India
  • 12.8 Bharat Biotech
  • 12.9 Gamaleya Research Institute
  • 12.10 Novavax
  • 12.11 CureVac
  • 12.12 CanSino Biologics
  • 12.13 Sanofi-GSK
  • 12.14 GlaxoSmithKline
  • 12.15 Entos Pharmaceuticals

List of Tables

  • Table 1 Global Coronavirus Vaccine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 3 Global Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
  • Table 4 Global Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
  • Table 5 Global Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
  • Table 6 Global Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
  • Table 7 Global Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
  • Table 8 Global Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
  • Table 9 Global Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 10 Global Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
  • Table 11 Global Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
  • Table 12 Global Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 13 Global Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 14 Global Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 15 Global Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
  • Table 16 Global Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 17 Global Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 18 Global Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 19 Global Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
  • Table 20 Global Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
  • Table 21 Global Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 22 Global Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
  • Table 23 Global Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
  • Table 24 Global Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 25 Global Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
  • Table 26 Global Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
  • Table 27 Global Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 28 North America Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
  • Table 29 North America Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 30 North America Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
  • Table 31 North America Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
  • Table 32 North America Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
  • Table 33 North America Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
  • Table 34 North America Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
  • Table 35 North America Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
  • Table 36 North America Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 37 North America Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
  • Table 38 North America Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
  • Table 39 North America Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 40 North America Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 41 North America Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 42 North America Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
  • Table 43 North America Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 44 North America Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 45 North America Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 46 North America Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
  • Table 47 North America Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
  • Table 48 North America Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 49 North America Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
  • Table 50 North America Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
  • Table 51 North America Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 52 North America Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
  • Table 53 North America Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
  • Table 54 North America Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 55 Europe Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
  • Table 56 Europe Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 57 Europe Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
  • Table 58 Europe Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
  • Table 59 Europe Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
  • Table 60 Europe Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
  • Table 61 Europe Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
  • Table 62 Europe Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
  • Table 63 Europe Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 64 Europe Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
  • Table 65 Europe Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
  • Table 66 Europe Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 67 Europe Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 68 Europe Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 69 Europe Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
  • Table 70 Europe Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 71 Europe Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 72 Europe Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 73 Europe Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
  • Table 74 Europe Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
  • Table 75 Europe Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 76 Europe Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
  • Table 77 Europe Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
  • Table 78 Europe Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 79 Europe Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
  • Table 80 Europe Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
  • Table 81 Europe Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 82 Asia Pacific Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
  • Table 83 Asia Pacific Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 84 Asia Pacific Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
  • Table 85 Asia Pacific Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
  • Table 86 Asia Pacific Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
  • Table 87 Asia Pacific Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
  • Table 88 Asia Pacific Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
  • Table 89 Asia Pacific Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
  • Table 90 Asia Pacific Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 91 Asia Pacific Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
  • Table 92 Asia Pacific Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
  • Table 93 Asia Pacific Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 94 Asia Pacific Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 95 Asia Pacific Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 96 Asia Pacific Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
  • Table 97 Asia Pacific Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 98 Asia Pacific Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 99 Asia Pacific Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 100 Asia Pacific Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
  • Table 101 Asia Pacific Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
  • Table 102 Asia Pacific Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 103 Asia Pacific Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
  • Table 104 Asia Pacific Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
  • Table 105 Asia Pacific Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 106 Asia Pacific Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
  • Table 107 Asia Pacific Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
  • Table 108 Asia Pacific Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 109 South America Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
  • Table 110 South America Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 111 South America Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
  • Table 112 South America Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
  • Table 113 South America Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
  • Table 114 South America Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
  • Table 115 South America Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
  • Table 116 South America Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
  • Table 117 South America Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 118 South America Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
  • Table 119 South America Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
  • Table 120 South America Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 121 South America Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 122 South America Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 123 South America Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
  • Table 124 South America Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 125 South America Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 126 South America Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 127 South America Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
  • Table 128 South America Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
  • Table 129 South America Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 130 South America Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
  • Table 131 South America Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
  • Table 132 South America Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 133 South America Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
  • Table 134 South America Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
  • Table 135 South America Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 136 Middle East & Africa Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
  • Table 137 Middle East & Africa Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 138 Middle East & Africa Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
  • Table 139 Middle East & Africa Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
  • Table 140 Middle East & Africa Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
  • Table 141 Middle East & Africa Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
  • Table 142 Middle East & Africa Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
  • Table 143 Middle East & Africa Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
  • Table 144 Middle East & Africa Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 145 Middle East & Africa Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
  • Table 146 Middle East & Africa Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
  • Table 147 Middle East & Africa Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 148 Middle East & Africa Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 149 Middle East & Africa Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 150 Middle East & Africa Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
  • Table 151 Middle East & Africa Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 152 Middle East & Africa Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 153 Middle East & Africa Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 154 Middle East & Africa Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
  • Table 155 Middle East & Africa Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
  • Table 156 Middle East & Africa Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 157 Middle East & Africa Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
  • Table 158 Middle East & Africa Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
  • Table 159 Middle East & Africa Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 160 Middle East & Africa Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
  • Table 161 Middle East & Africa Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
  • Table 162 Middle East & Africa Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)